SPOTLIGHT: AstraZeneca wants FDA ad review

by admin |


AstraZeneca is lobbying Congress for FDA review of television ads. Last fall lawmakers created a program that would require up-front scrutiny of DTC ads, but didn't give the FDA authority to collect and spend industry fees to fund it. Report

Suggested Articles

repatha
Pharma

AHA: Amgen's Repatha more effective in high-risk CV patients

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

by Kyle Blankenship
Jardiance
Pharma

AHA: Lilly, BI's Jardiance drops CV hospitalizations over rivals

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

by Kyle Blankenship
AstraZeneca
Pharma

AHA: Solo Brilinta linked to less bleeding in ACS patients

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

by Kyle Blankenship